Compare BCBP & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BCBP | MSLE |
|---|---|---|
| Founded | 2000 | N/A |
| Country | United States | Canada |
| Employees | N/A | 17 |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.1M | 146.9M |
| IPO Year | 2005 | N/A |
| Metric | BCBP | MSLE |
|---|---|---|
| Price | $10.29 | $8.47 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 91.1K | 49.9K |
| Earning Date | 04-21-2026 | N/A |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $85.26 | N/A |
| Revenue Next Year | $6.14 | N/A |
| P/E Ratio | $39.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.31 | $5.50 |
| 52 Week High | $10.50 | $13.39 |
| Indicator | BCBP | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 65.25 | 57.78 |
| Support Level | $7.49 | $6.73 |
| Resistance Level | N/A | $9.50 |
| Average True Range (ATR) | 0.28 | 0.75 |
| MACD | -0.00 | 0.19 |
| Stochastic Oscillator | 75.56 | 60.81 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.